x
Breaking News
0

Incyte Corporation (INCY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Incyte's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
109.69 -1.16    -1.05%
19:59:59 GMT - Closed. Currency in USD ( Disclaimer )
After Hours
109.62
-0.07
-0.07%
20:07:43 GMT - Real-time Data
Type: Equity
Market: United States
ISIN: US45337C1027 
CUSIP: 45337C102
  • Volume: 2,924,255
  • Bid/Ask: 109.05 / 111.00
  • Day's Range: 107.79 - 110.80
START TRADING NOW
Incyte 109.69 -1.16 -1.05%

INCY Overview

 
Information about the Incyte Corporation Stock. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close109.69
Day's Range107.79 - 110.8
Revenue1.31B
Open110.43
52 wk Range83.01 - 153.15
EPS - 0.78
Volume2,924,255
Market Cap23.35B
Dividend (Yield)0 (N/A)
Average Vol. (3m)1,417,371
P/E RatioN/A
Beta0.93
1-Year Change24.58%
Shares Outstanding210,649,731
Next Earnings DateOct 30, 2017

Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Strong Sell Strong Sell Strong Sell Strong Sell Buy
Technical Indicators Strong Sell Strong Sell Strong Sell Strong Sell BUY
Summary Strong Sell Strong Sell Strong Sell Strong Sell Buy

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Hanging Man 15 Current
Engulfing Bearish 1M Current
Completed Patterns
Downside Gap Three Methods 30 2 Sep 25, 2017 02:30PM
Three Inside Up 1W 4 Aug 27, 2017
Abandoned Baby Bearish 30 4 Sep 25, 2017 01:30PM

Incyte Corporation News & Analysis

News


Incyte Corporation Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 109.69 109.05 111.00 2,924,255 -1.05% USD 19:59:59  
  Berlin 92.21 91.65 91.87 0 -1.42% EUR 16:42:00  
  Stuttgart 92.00 0.00 0.00 0 -1.65% EUR 14:49:00  
  Munich 93.44 0.00 0.00 0 -1.91% EUR 06:03:00  
  Vienna 92.430 0.000 0.000 0 -1.48% EUR 15:32:00  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Apple 150.55 151.83 149.16 -1.34 -0.88% 43.95M 19:59:59  
  Facebook 162.87 169.30 161.56 -7.67 -4.50% 40.55M 19:59:59  
  Amazon.com 939.79 949.42 932.89 -15.31 -1.60% 5.07M 19:59:59  
  Alibaba 169.59 177.00 167.50 -8.55 -4.80% 33.96M 19:59:59  
  Tesla 344.99 357.47 342.88 -6.10 -1.74% 7.55M 19:59:59  
  NVIDIA 171.00 177.80 170.16 -8.00 -4.47% 21.64M 19:59:59  
  AMD 12.610 13.280 12.490 -0.690 -5.19% 83.53M 19:59:59  
  Netflix 178.55 186.55 177.70 -8.80 -4.70% 9.33M 19:59:59  
  Micron 34.87 36.15 34.54 -1.20 -3.33% 35.40M 19:59:59  
  ITUS Corp 3.850 4.300 2.200 +1.580 +69.60% 14.69M 19:59:59  

Incyte Corporation Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

980

Equity Type

ORD

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
National Futures Association (United States), National Securities Depository (India), U.S. Commodity Futures Trading Commission (United States), The Financial Conduct Authority (United Kingdom), Financial Industry Regulatory Authority (United States), Investment Industry Regulatory Organization of Canada (Canada), Securities and Exchange Board of India (India), Securities and Exchange Commission (United States), The Securities and Futures Commission (Hong Kong), Securities Investor Protection Corporation (United States) $10000 Start Trading
U.S. Commodity Futures Trading Commission (United States) $250 Start Trading
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) Start Trading
U.S. Commodity Futures Trading Commission (United States) Start Trading

My Sentiments

What is your sentiment on Incyte?
or
Market is currently closed. Voting is open during market hours.

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

 
Are you sure you want to delete this chart?
 
Write your thoughts about Incyte Corporation
 
Replace the attached chart with a new chart ?
Post
Post also to:
1000
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
 
Replace the attached chart with a new chart ?
Post 1000
Please wait a minute before you try to comment again.
 
 
 
Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Add Chart to Comment
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email